{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T02:54:49Z","timestamp":1764557689041,"version":"3.41.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["eTrack #214738"],"award-info":[{"award-number":["eTrack #214738"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1136\/ijgc-2023-004484","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:30:26Z","timestamp":1700829026000},"page":"1898-1905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct04785716","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05329545","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-415X","authenticated-orcid":false,"given":"Bente","family":"Vilming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen","family":"Fall\u00e5s Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Gry","family":"Bentzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke Anett","family":"Ingebrigtsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Berge Nilsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingvild","family":"Vistad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"D\u00f8rum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-3453","authenticated-orcid":false,"given":"Olesya","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-2770","authenticated-orcid":false,"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Zucknick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guro","family":"Aune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"ECIS - European cancer information system","year":"2020","key":"10.1136\/ijgc-2023-004484_bb0010"},{"journal-title":"Cancer in Norway 2019 - cancer incidence, mortality, survival and prevalence in Norway Oslo cancer Registry of Norway","year":"2020","key":"10.1136\/ijgc-2023-004484_bb0015"},{"key":"10.1136\/ijgc-2023-004484_bb0020","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2023-004484_bb0025","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive Relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004484_bb0030","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004484_bb0035","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004484_bb0040","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with Olaparib maintenance after chemotherapy in patients with platinum-sensitive, Relapsed ovarian cancer and a Brca1\/2 Mutation (Solo2\/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0045","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1136\/ijgc-2023-004484_bb0050","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from Solo2\/ENGOT-Ov21: A phase III trial assessing maintenance Olaparib in patients (Pts) with platinum-sensitive, Relapsed ovarian cancer and a BRCA Mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"JCO"},{"key":"10.1136\/ijgc-2023-004484_bb0055","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004484_bb0060","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate Rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-Ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0065","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004484_bb0070","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus Bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-Ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0075","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.19.02745","article-title":"Olaparib versus Nonplatinum chemotherapy in patients with platinum-sensitive Relapsed ovarian cancer and a Germline Brca1\/2 Mutation (Solo3): A randomized phase III trial","volume":"38","author":"Penson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","article-title":"Rucaparib versus standard-of-care chemotherapy in patients with Relapsed ovarian cancer and a deleterious Brca1 or Brca2 Mutation (Ariel4): an international, open-label, randomised, phase 3 trial","volume":"23","author":"Kristeleit","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0085","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1021\/jm901188v","article-title":"Discovery of 2-4-[(3S)-Piperidin-3-Yl]Phenyl-2H-Indazole-7-Carboxamide (MK-4827): a novel oral Poly(ADP-Ribose)Polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors","volume":"52","author":"Jones","year":"2009","journal-title":"J Med Chem"},{"key":"10.1136\/ijgc-2023-004484_bb0090","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a Multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1136\/ijgc-2023-004484_bb0095","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/annonc\/mdy255","article-title":"Safety and dose modification for patients receiving Niraparib","volume":"30","author":"Berek","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying Prognostic Comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1136\/ijgc-2023-004484_bb0110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2023-004484_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","article-title":"Olaparib as maintenance therapy in patients with BRCA 1-2 Mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome","volume":"156","author":"Cecere","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0120","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11523-018-0604-z","article-title":"Real-world use and outcomes of Olaparib: a population-based cohort study","volume":"13","author":"Eriksson","year":"2018","journal-title":"Target Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2020.07.020","article-title":"Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice","volume":"159","author":"Eakin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10191-5","article-title":"Rucaparib in recurrent ovarian cancer: real-world experience from the Rucaparib early access programme in Spain - A GEICO study","volume":"22","author":"Yubero","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2023-004484_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2022.12.014","article-title":"Real-world applications of Parpi maintenance therapy for recurrent ovarian cancer: A single-center study in China","volume":"170","author":"Wang","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2023-004484_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx372.036","article-title":"Evaluation of tumour responses and Olaparib efficacy in platinum-sensitive Relapsed ovarian cancer (PSROC) patients (Pts) with or without measurable disease in the Solo2 trial (ENGOT Ov-21)","volume":"28","author":"Oza","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1136\/ijgc-2023-004484_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.950","article-title":"811Mo maintenance Olaparib for patients (Pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA Mutation (Brcam): 5-year (Y) follow-up (f\/U) from Solo1","volume":"31","author":"Banerjee","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1136\/ijgc-2023-004484_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061607","article-title":"Overcoming platinum and PARP-inhibitor resistance in ovarian cancer","volume":"12","author":"McMullen","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004484_bb0155","doi-asserted-by":"crossref","first-page":"v351","DOI":"10.1093\/annonc\/mdx372.058","article-title":"Oreo\/ENGOT Ov-38: A phase IIIB trial of Olaparib maintenance Retreatment in patients with epithelial ovarian cancer","volume":"28","author":"Pujade-Lauraine","year":"2017","journal-title":"Annals of Oncology"},{"year":"2023","author":"clinicaltrials.gov","key":"10.1136\/ijgc-2023-004484_bb0160"},{"key":"10.1136\/ijgc-2023-004484_bb0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ygyno.2023.03.019","article-title":"Maintenance Olaparib in patients with platinum-sensitive Relapsed ovarian cancer: outcomes by somatic and Germline BRCA and other Homologous Recombination repair gene Mutation status in the ORZORA trial","volume":"172","author":"Pignata","year":"2023","journal-title":"Gynecologic Oncology"},{"key":"10.1136\/ijgc-2023-004484_bb0170","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/Homologous Recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:40:55Z","timestamp":1753224055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24014610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1048891X24014610"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004484","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}